The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Patients in the ixazomib, and oral proteosome inhibitor, plus lenalidomide and dexamethasone arm had a 6-month benefit on progression-free survival (PFS).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
